EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy

Christian Vaccarin, Darja Beyer, Jerome V Schmid, Bastian Klein, Jathursa Jegathasan, Shreshtha Behera, Xavier Deupi, Roger Schibli, Cristina Müller iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-03 · 53 (4) · 2502-2517

DOI: 10.1007/s00259-025-07602-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.10.2025. Verfasst von Christian Vaccarin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator, Radioisotopes, Peptides, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PSI - Paul Scherrer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to develop radiopeptides for targeting the urokinase-type plasminogen activator receptor (uPAR) modified with an albumin-binding moiety to improve their tissue distribution profiles. Methods uPAR-11, uPAR-12, uPAR-14, uPAR-15, uPAR-17 and uPAR-18 were synthesized based on the AE105 nonapeptide which was modified with the p -tolyl-based albumin binder and variable linker entities and chelators. The 177 Lu-labeled peptides were evaluated in vitro with regard to their stability, albumin-binding properties and uPAR-binding affinity using HEK-uPAR cells. Biodistribution and SPECT/CT imaging studies were performed with HEK-uPAR xenografted nude mice. The acquired data were compared to those obtained with [ 177 Lu]Lu-DOTA-AE105.

Results

The radiopeptides showed 11‒155-fold higher albumin-binding affinity in human blood plasma than [ 177 Lu]Lu-DOTA-AE105. The uPAR-binding affinity reached K D values of 31‒42 nM, similar to the K D value of 20 ± 1 nM determined for [ 177 Lu]Lu-DOTA-AE105. Accumulation in the HEK-uPAR xenograft was 6.0–16% IA/g at 4 h p.i., which was 7‒18-fold higher than that of [ 177 Lu]Lu-DOTA-AE105. PEG spacers next to the albumin binder as exemplified in [ 177 Lu]Lu-uPAR-11, [ 177 Lu]Lu-uPAR-15 and [ 177 Lu]Lu-uPAR-18 led to increased xenograft accumulation while their replacement with an alkane spacer in [ 177 Lu]Lu-uPAR-12 led to unfavorably high blood retention. A diaminopropionic acid to connect the different entities did not improve the tissue distribution profile of [ 177 Lu]Lu-uPAR-14 as compared to other peptides which were designed with a lysine residue. The use of a DOTAGA chelator instead of a DOTA resulted in unfavorable kidney retention of [ 177 Lu]Lu-uPAR-17.

Conclusion

In view of a clinical translation, [ 177 Lu]Lu-uPAR-11 emerged as the most favorable candidate. Future studies will, thus, focus on the therapeutic potential of [ 177 Lu]Lu-uPAR-11 in tumor-bearing mice. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Urokinase Plasminogen ActivatorRadioisotopesPeptidesRadiopharmaceuticalsAnimalsHumansMiceTissue DistributionLutetiumMice, NudeHEK293 CellsSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

p-tolyl entityAlbumin binderDOTA-AE105Lutetium-177SPECT imagingUrokinase-type plasminogen activator receptoruPAR

Substanzen

Receptors, Urokinase Plasminogen ActivatorRadioisotopesLutetiumPeptidesLutetium-177Radiopharmaceuticals

Autor:innen und Institutionen

  • Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland.
  • Condensed Matter Theory Group, PSI Center for Scientific Computing, Theory and Data, Villigen-PSI, 5232, Switzerland.
  • Laboratory of Biomolecular Research, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland.
  • Swiss Institute of Bioinformatics (SIB), Lausanne, 1015, Switzerland.
  • Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland.
  • Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland. cristina.mueller@psi.ch.

ORCID-Profile: Cristina Müller

Förderung

  • PSI - Paul Scherrer Institute

Zitieren

APA

Vaccarin, C., Beyer, D., Schmid, J. V., Klein, B., Jegathasan, J., Behera, S., Deupi, X., Schibli, R., & Müller, C. (2026). Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(4), 2502-2517. https://doi.org/10.1007/s00259-025-07602-7

Vancouver

Vaccarin C, Beyer D, Schmid JV, Klein B, Jegathasan J, Behera S, et al. Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(4):2502-2517. doi:10.1007/s00259-025-07602-7

BibTeX
@article{Vaccarin2026,
  author = {Vaccarin, Christian and Beyer, Darja and Schmid, Jerome V and Klein, Bastian and Jegathasan, Jathursa and Behera, Shreshtha and Deupi, Xavier and Schibli, Roger and Müller, Cristina},
  title = {Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {4},
  pages = {2502--2517},
  doi = {10.1007/s00259-025-07602-7}
}
Kostenlos starten →